Phase I/II study of PhageBank™ therapy in conjunction with standard of care versus standard of care in patients with diabetic foot osteomyelitis
Latest Information Update: 05 Apr 2024
At a glance
- Drugs Bacteriophage therapeutics-BiomX (Primary)
- Indications Diabetic foot; Osteomyelitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms DANCE
- Sponsors Adaptive Phage Therapeutics
Most Recent Events
- 03 Apr 2024 According to a BiomX media release, to date, 32 patients have been enrolled.
- 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
- 06 Mar 2024 According to a BiomX media release, the phase 2 of study is expected to enroll 45 patients in the trial. A first readout of study topline results is expected at week 13 evaluating healing of the wound associated with osteomyelitis, followed by a second readout at week 52 evaluating amputation rates and resolution of osteomyelitis based on X-ray, clinical assessments, and established biomarkers (ESR and CRP). These readouts are expected in the first quarter of 2025 and the first quarter of 2026.